Cite
Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia
MLA
Faisal M Sanai, et al. “Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide versus Continuing on Entecavir in Chronic Hepatitis B Patients with Low-Level Viremia in Saudi Arabia.” The Saudi Journal of Gastroenterology, vol. 30, no. 1, Jan. 2024, pp. 23–29. EBSCOhost, https://doi.org/10.4103/sjg.sjg_170_23.
APA
Faisal M Sanai, Mohammed Aljawad, Abdullah Saeed Alghamdi, Alon Yehoshua, Abdullah Khathlan, Mohammed Alghamdi, Sam Kozma, Nathaniel Smith, Fadoua El-Moustaid, Sushanth Jeyakumar, & Nandita Kachru. (2024). Long-term health and economic benefits of switching to tenofovir alafenamide versus continuing on entecavir in chronic hepatitis B patients with low-level viremia in Saudi Arabia. The Saudi Journal of Gastroenterology, 30(1), 23–29. https://doi.org/10.4103/sjg.sjg_170_23
Chicago
Faisal M Sanai, Mohammed Aljawad, Abdullah Saeed Alghamdi, Alon Yehoshua, Abdullah Khathlan, Mohammed Alghamdi, Sam Kozma, et al. 2024. “Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide versus Continuing on Entecavir in Chronic Hepatitis B Patients with Low-Level Viremia in Saudi Arabia.” The Saudi Journal of Gastroenterology 30 (1): 23–29. doi:10.4103/sjg.sjg_170_23.